STA
IMGN

Summit Trail Advisors’s Immunogen Inc IMGN Stock Holding History

Summit Trail Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,635
Closed -$123K – 468
2018
Q2 		$123K Sell
12,635
-24,189
-66% -$255K 0.04% 188
2018
Q1 		$240K Buy
36,824
+4,255
+13% +$42K 0.04% 331
2017
Q4 		$256K Buy
+32,569
New +$201K 0.03% 356

Other funds holding IMGN

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Summit Trail Advisors's IMGN Position: Q3 2018 in Review

Summit Trail Advisors sold out of Immunogen Inc (IMGN) in Q3 2018, closing a stake of 12,635 shares — an estimated $123K sold.

Summit Trail Advisors first reported a position in IMGN in Q4 2017 and held it in 3 quarters. The position peaked at $256K in Q4 2017. 208 funds tracked by Wall St. Rank hold IMGN as of Q3 2018.

  • Summit Trail Advisors reported no remaining Immunogen Inc position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 12,635 Immunogen Inc shares in Q3 2018, an estimated $123K.
  • Summit Trail Advisors first reported a position in Immunogen Inc in Q4 2017 and held it in 3 quarters.
  • Summit Trail Advisors's Immunogen Inc position peaked at $256K in Q4 2017.
  • 208 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.